Anthera Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Anthera Pharmaceuticals's estimated annual revenue is currently $3.1M per year.
- Anthera Pharmaceuticals's estimated revenue per employee is $147,619
- Anthera Pharmaceuticals's total funding is $101.5M.
Employee Data
- Anthera Pharmaceuticals has 21 Employees.
- Anthera Pharmaceuticals grew their employee count by -12% last year.
Anthera Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|
Anthera Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Anthera Pharmaceuticals?
Anthera Pharmaceuticals is a start-up pharmaceutical company focused on the in-licensing of promising clinical candidates for the treatment of serious respiratory and inflammatory diseases. Anthera has identified four clinical stage products which have the potential address a variety of these target diseases including: Acute Lung Injury, Cystic Fibrosis, COPD, Asthma, and idiopathic pulmonary fibrosis.
keywords:N/A
$101.5M
Total Funding
21
Number of Employees
$3.1M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Anthera Pharmaceuticals News
Ocuphire Pharma, Inc.: Jay Pepose was appointed chief medical adviser of ... he served as president and CEO of Anthera Pharmaceuticals,...
Before his turn as Neurana's chief, Thompson was president and CEO of Anthera Pharmaceuticals and the COO at Tetraphase. Christopher Slapak. ?...
Taking his place as CEO is Craig Thompson, who previously led Neurana Pharmaceuticals and Anthera Pharmaceuticals.
Anthera Pharmaceuticals has raised $19 million in a second round of funding led by Caxton Advantage Life Sciences Fund and HBM BioCapital. Existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi International Corporation also participated. The San Ma ...
San Francisco’s Anthera Pharmaceuticals, which develops treatments for inflammatory diseases, said it has gotten $36 million in initial venture financing. The funding was co-led by VantagePoint Venture Partners and Sofinnova Ventures, and included Pappas Ventures, Mitsubishi International Corpo ...
Other Companies in Hayward
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 21 | 0% | N/A |
#2 | $3.3M | 21 | -36% | N/A |
#3 | $7.5M | 21 | -5% | N/A |
#4 | $4.3M | 21 | -51% | N/A |
#5 | $4.8M | 21 | -5% | N/A |